Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 6/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GYS1 | P13807 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19475165 | 1.00 | ALDH1A1 (0.39) | ALDH1A1GRM5KMT2AL3MBTL1DRD2 | |
| SCHEMBL19505788 | 0.90 | L3MBTL1 (0.36) | ALDH1A1GRM5KMT2AL3MBTL1DRD2 | |
| SCHEMBL19475150 | 0.89 | L3MBTL1 (0.42) | ALDH1A1KMT2AL3MBTL1MEN1 | |
| SCHEMBL19474997 | 0.84 | L3MBTL1 (0.31) | ALDH1A1L3MBTL1 | |
| SCHEMBL19474996 | 0.84 | L3MBTL1 (0.31) | ALDH1A1L3MBTL1 | |
| SCHEMBL19475396 | 0.81 | NPSR1 (0.38) | ALDH1A1KMT2AL3MBTL1DRD2DRD3 | |
| SCHEMBL19475398 | 0.81 | NPSR1 (0.38) | ALDH1A1KMT2AL3MBTL1DRD2DRD3 | |
| SCHEMBL19475762 | 0.80 | NFKB1 (0.33) | — | |
| SCHEMBL20996808 | 0.80 | GRM5 (0.42) | ALDH1A1GRM5KMT2AL3MBTL1NAAA | |
| SCHEMBL19475397 | 0.80 | SMN1; SMN2 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647671-B2 | Promysalin analogues and methods of use thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190161444-A1 | Novel Promysalin Analogues and Methods of Use Thereof | Temple University--of the Commonwealth System of Higher Education | 2019-05-30 | — | — | US | disclosed |
| WO-2017184558-A1 | NOVEL PROMYSALIN ANALOGUES AND METHODS OF USE THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647671-B2 | Promysalin analogues and methods of use thereof | CCL11, MAN2A1, PREP | ALDH1A1 2458/4885GRM5 2921/4885KMT2A 1988/4885 |
| US-20190161444-A1 | Novel Promysalin Analogues and Methods of Use Thereof | MASP2, MAN2A1, CCL11 | ALDH1A1 2906/4885GRM5 3246/4885KMT2A 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.